IN THE SPOTLIGHT

FDA Awards Breakthrough Therapy Designation to Novel HER2-Activating NSCLC Therapy

FDA Awards Breakthrough Therapy Designation to Novel HER2-Activating NSCLC Therapy

FDA Grants Breakthrough Therapy Designation to BAY 2927088 for HER2-Mutated NSCLC

FDA Grants Breakthrough Therapy Designation to BAY 2927088 for HER2-Mutated NSCLC

Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer

Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

ROS1-Positive NSCLC Represents a Targetable Mutation for New Therapies

ROS1-Positive NSCLC Represents a Targetable Mutation for New Therapies

Repotrectinib May Serve as a New Standard of Care Across Treatment Lines in ROS1+ NSCLC

Repotrectinib May Serve as a New Standard of Care Across Treatment Lines in ROS1+ NSCLC

FDA Approves Repotrectinib for ROS1-Positive NSCLC

FDA Approves Repotrectinib for ROS1-Positive NSCLC

FDA Approves Next-Generation Tyrosine Kinase Inhibitor Repotrectinib for ROS1-Positive NSCLC

FDA Approves Next-Generation Tyrosine Kinase Inhibitor Repotrectinib for ROS1-Positive NSCLC